Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00421031 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause
A Phase 3 study of Vasomotor Symptoms, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 540
- Enrollment target
- 20
- Study locations
NCT00421031: Completed Phase 3 study of Vasomotor Symptoms, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00421031 is a Phase 3 study of Vasomotor Symptoms that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 540 participants, above the 132-participant average among 8 other Vasomotor Symptoms trials with a reported enrollment target (309% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00421031, a Phase 3 study of Vasomotor Symptoms, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 540 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of 4 doses of desvenlafaxine-233 sustained release (DVS-233 SR) as compared to placebo for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as its influence on sleep parameters and other health outcomes indicators.
Conditions Studied
Interventions
- DRUG DVS-233 SR
Study Locations (20)
Florida
- - Aventura
- - Fort Myers
- - Inverness
- - Miami
- - New Port Richey
- - Ocala
- - Orange City
- - Pinellas Park
- - Tampa
- - West Palm Beach
- - West Venice
California
- - San Diego
- - Stanford
Georgia
- - Atlanta
- - Savannah
Alabama
- - Montgomery
Arizona
- - Peoria
Colorado
- - Colorado Springs
Delaware
- - Newark
Indiana
- - Newburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2003-12 |
| Est. Completion | 2004-04 |
| Phase | Phase 3 |
What the finished NCT00421031 record still lists
NCT00421031 is an interventional study that assigns participants to a tested intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap, above the 132-participant average among 8 other Vasomotor Symptoms trials with a reported enrollment target (309% higher).
The record links to 1 condition, with Vasomotor Symptoms appearing as the primary indexed condition, and to 1 intervention - of which DVS-233 SR is the first listed.
NCT00421031 names 20 study sites across 8 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT00421031 about?
NCT00421031 is a clinical study titled "Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause". The purpose of this study is to assess the efficacy and safety of 4 doses of desvenlafaxine-233 sustained release (DVS-233 SR) as compared to placebo for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as its influence on sleep parameters and other health ou...
What is the current status of trial NCT00421031?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 540 participants. The study started on 2003-12. Estimated completion is 2004-04.
What conditions does trial NCT00421031 study?
This clinical trial studies the following conditions: Vasomotor Symptoms.
What interventions are being tested in trial NCT00421031?
The interventions under investigation include: DVS-233 SR (DRUG).
Who is sponsoring clinical trial NCT00421031?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00421031 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vasomotor Symptoms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00421031's enrollment target sits among peer trials
540 1st of 8 higher than 8 of 8 other Vasomotor Symptoms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Vasomotor Symptoms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).
RECRUITING · Phase 2
-
Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture
RECRUITING · NA
-
JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women
RECRUITING · NA
-
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
RECRUITING · Phase 2
-
Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women
COMPLETED · NA
-
FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia